In recent trading session, CureVac N.V. (NASDAQ:CVAC) saw 0.91 million shares changing hands at last check today with its beta currently measuring 0. Company’s recent per share price level of $24.01 trading at -$3.02 or -11.17% at last check today assigns it a market valuation of $5.03B. That most recent trading price of CVAC’s stock is at a discount of -453.94% from its 52-week high price of $133.00 and is indicating a discount of -12.29% from its 52-week low price of $26.96. Taking a look at company’s average trading volume of 695.31K if we extend that period to 3-months.
For CureVac N.V. (CVAC), analysts’ consensus is at an average recommendation of a Hold while assigning it a mean rating of 3.20. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
CureVac N.V. (NASDAQ:CVAC) trade information
Upright in the red during last session for losing -11.17%, in the last five days CVAC remained trading in the red while hitting it’s week-highest on Monday, 01/10/22 when the stock touched $24.01 price level, adding 22.4% to its value on the day. CureVac N.V.’s shares saw a change of -21.22% in year-to-date performance and have moved -11.58% in past 5-day. CureVac N.V. (NASDAQ:CVAC) showed a performance of -29.92% in past 30-days.
Wall Street analysts have assigned a consensus price target of $39.06 to the stock, which implies a rise of 38.53% to its recent value today. Analysts have been projecting $17.76 as a low price target for the stock while placing it at a high target of $61.99. It follows that stock’s current price would drop -158.18% in reaching the projected high whereas dropping to the targeted low would mean a gain of 26.03% for stock’s current value.
CureVac N.V. (CVAC) estimates and forecasts
Statistics highlight that CureVac N.V. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -46.22% of value to its shares in past 6 months, showing an annual growth rate of 35.71% while that of industry is 7.90. Apart from that, the company came raising its revenue forecast for fiscal year 2022. This year revenue growth is estimated to rise 52.50% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $11.3 million for the same. And 2 analysts are in estimates of company making revenue of $25.32 million in the next quarter that will end on Jun 2021.
CureVac N.V. is more likely to be releasing its next quarterly report on November 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
CureVac N.V. (NASDAQ:CVAC)’s Major holders
Insiders are in possession of 54.87% of company’s total shares while institution are holding 23.39 percent of that, with stock having share float percentage of 51.83%. Investors also watch the number of corporate investors in a company very closely, which is 23.39% institutions for CureVac N.V. that are currently holding shares of the company. Baillie Gifford and Company is the top institutional holder at CVAC for having 3.94 million shares of worth $215.24 million. And as of Sep 29, 2021, it was holding 2.11% of the company’s outstanding shares.
The second largest institutional holder is Bill & Melinda Gates Foundation, which was holding about 3.13 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 1.68% of outstanding shares, having a total worth of $171.22 million.
On the other hand, Vanguard International Growth Fund and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Aug 30, 2021, the former fund manager was holding 2.73 million shares of worth $179.83 million or 1.46% of the total outstanding shares. The later fund manager was in possession of 0.41 million shares on Sep 29, 2021, making its stake of worth around $22.17 million in the company or a holder of 0.22% of company’s stock.